Hematology Market will be Valued CAGR at 5% by 2023 | Global Key Players – ABBOTT LABORATORIES, AGILENT TECHNOLOGIES, BIO-RAD LABORATORIES, DANAHER CORPORATION, DOLOMITE CENTRE, F. HOFFMANN-LA ROCHE AG

Global Hematology Market Highlights
"The Hematology Market is expected to register a CAGR of about 5%, during the forecast period, 2018 to 2023. Hematology market is set to witness growth in the forecasted instruments are emerging as vital diagnostic tools used in testing, counting, measuring, and analyzing red blood cells, WBC, and platelets.

Get your sample report now @ https://marketprognosis.com/sample-request/17051
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Incidences of Blood Disorders
The incidences of blood-related disorders are increasing rapidly globally. Approximately one person is diagnosed with blood cancer every 3 minutes in the US. Serious blood disorders, which might lead to the use of hematology include anemia, malaria, thalassemia, myelodysplastic syndrome, etc. Along with this, the rising incidence of kidney diseases is expected to induce huge growth in the hematology market. Also, with this other factors, such as rapid technological advances and emergence of high throughput hematology analyzers are boosting the market growth.

Key Developments in the Market
November 2017 - Sysmex Acquired CLIA Waiver for New Automated Hematology Analyzeru2014The First Automated Hematology Analyzer to Receive Such Approval.

Major Players:
ABBOTT LABORATORIES, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES INC., DANAHER CORPORATION, DOLOMITE CENTRE, F. HOFFMANN-LA ROCHE AG, FLUIDIGM CORPORATION, MICRONIT MICROFLUIDICS BV, PERKINELMER INC., THERMO FISHER SCIENTIFIC INC., AND UFLUIDIX, amongst others.
Get Discount on this report @ https://marketprognosis.com/discount-request/17051
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Low Adoption of Hematology Analyzers in Emerging Economies
Hematology analyzers are large automated integrated systems that combine all forms of sample processing, analysis, and presentation of results. They also help in pre and post-analytical sample handling and management of reagent supply with limited user interference. These systems help laboratories generate results in faster turnaround time, thereby improving the efficiency and labor utilization. These instruments are expensive capital equipment and emerging economies are largely unable to afford them in spite of the ease at which the results are rendered, and the accuracy of the results hematology analyzers provide. This acts as a restraint for the growth of the hematology market. The high cost of equipment and reagents along with poor health insurance coverage slow down the growth of the hematology market.

North to Witness Considerable Growth in the Forecast Period
North America is currently the largest market for hematology analyzers. This market trend can be attributed to the increasing incidence of blood disorders. More and more cases of blood-related disorders, such as anemia, blood cancer, etc. will lead to the growth of the market of hematology. Europe is the second-largest market while Asia-Pacific is the fastest growing region.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/17051
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.